Development of Nanoproteomic Technologies

纳米蛋白质组学技术的发展

• 批准号: 8321507
• 负责人: CHENG S LEE
• 金额: $ 18.75万
• 依托单位: UNIV OF MARYLAND, COLLEGE PARK
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-01 至 2014-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8321507
• 关键词: Biological; Biological Markers; Blood capillaries; Caliber; Cancer Patient; Carcinoma in Situ; Chromatography; Complex; Coupled; Couples; Detection; Development; Diagnostic; Disease; Disease Progression; Early Diagnosis; Electrophoresis; Epithelium; Etiology; Evaluation; Gene Proteins; Investigation; Ions; Laboratories; Length; Lesion; Liquid Chromatography; Malignant Neoplasms; Microdissection; Molecular; Molecular Profiling; Ovarian Carcinoma; Ovarian Serous Adenocarcinoma; Peptides; Performance; Phase; Phenotype; Prevention; Process; Proteins; Proteome; Proteomics; Relative (related person); Reproducibility; Research; Research Personnel; Risk Factors; Sampling; Sequence Analysis; Signal Transduction; Specimen; Spectrometry, Mass, Electrospray Ionization; System; TP53 gene; Technology; Therapeutic; Tissue Model; Tissues; Tubular formation; Work; base; cancer prevention; capillary; comparative; disorder risk; improved; laser capture microdissection; neoplastic cell; novel; precursor cell; protein expression; protein profiling; technology development; tumor

DESCRIPTION (provided by applicant): It has been well accepted that molecular profiling in tumor precursor lesions is fundamental to understand the molecular etiology in tumor development and to provide the potential biomarkers for early detection and prevention. Furthermore, the need to detect weak indications or small but biologically important changes in protein expression profiles remains, as cancer researchers explore the initial steps in biological-signaling cascades and compensatory processes. However, in the absence of PCR-like protein amplification, comprehensive and quantitative analysis of protein expression within 102-103 tumor cells (corresponding to a total protein content of 10-100 ng) microdissected from very tiny precursor lesions such as tubal intraepithelial carcinoma represents a daunting task which necessitates highly sensitive analytical approaches, exceeding the dynamic range of currently available proteomic platforms. Thus, the proposed research aims to develop and demonstrate an effective discovery-based nanoproteomic platform, which enables ultrasensitive and comprehensive studies of protein profiles that will have diagnostic and therapeutic relevance.

描述（由申请方提供）：肿瘤前体病变的分子谱分析对于了解肿瘤发展的分子病因学以及为早期检测和预防提供潜在生物标志物是非常重要的，这一点已被广泛接受。此外，需要检测蛋白质表达谱中的弱指示或小但具有生物学重要性的变化，因为癌症研究人员正在探索生物信号级联和补偿过程的初始步骤。然而，在没有PCR样蛋白扩增的情况下，全面定量分析102-103肿瘤细胞内的蛋白表达（对应于10-100 ng的总蛋白质含量）从非常微小的前体病变如输卵管上皮内癌中显微解剖的方法代表了一项艰巨的任务，其需要高度灵敏的分析方法，超过了目前可用的蛋白质组学平台的动态范围。因此，拟议的研究旨在开发和展示一种有效的基于发现的纳米蛋白质组学平台，该平台能够对具有诊断和治疗相关性的蛋白质谱进行超灵敏和全面的研究。